All Atrial fibrillation articles
Patients with atrial fibrillation report fewer adverse renal outcomes and a slower decline in renal function on rivaroxaban compared with warfarin
Upcoming Live Webinars
The impact of DOACs on stroke in patients with NVAF: practical considerations for those with comorbidities
This promotional webinar has been funded by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance and organised in partnership with Guidelines.
ELIQUIS (apixaban) prescribing and adverse event reporting information.
432-GB-2100774 | August 2021
This animation has been developed and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals.
432-GB-2100230 June 2021
This video has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View Xarelto▼(rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-1924 January 2021
Independent professional body guideline
Recommendations for primary care on the role of oral anticoagulant treatment in people with non-valvular atrial fibrillation.
Working party guideline/algorithm
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.
Read the latest recommendations on the management of atrial fibrillation and ventricular arrhythmias in acute coronary syndrome, coronary heart disease, and left-ventricular dysfunction as well as arrhythmias associated with cardiac arrest and coronary artery bypass graft.